Amphastar Pharmaceuticals (AMPH) Earns Daily Coverage Optimism Rating of 0.18
Media coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.7335703434814 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Amphastar Pharmaceuticals (AMPH) Stock Rating Upgraded by BidaskClub (americanbankingnews.com)
- Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Earnings of -$0.04 Per Share (americanbankingnews.com)
- Amphastar Pharmaceuticals Inc (AMPH) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Tracking Analyst Views on Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) – SCY News (scynews.com)
Several analysts recently weighed in on the company. Piper Jaffray Companies set a $19.00 price objective on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 22nd. BidaskClub lowered Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 9th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Needham & Company LLC raised their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, December 1st. Finally, Jefferies Group set a $19.00 price objective on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $19.50.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.05. The business had revenue of $57.90 million for the quarter, compared to analyst estimates of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. Amphastar Pharmaceuticals’s revenue was down 9.8% compared to the same quarter last year. During the same period last year, the firm posted $0.14 earnings per share. equities analysts predict that Amphastar Pharmaceuticals will post -0.03 EPS for the current fiscal year.
In other news, Director Stephen B. Shohet sold 7,866 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $18.87, for a total transaction of $148,431.42. Following the sale, the director now directly owns 31,982 shares of the company’s stock, valued at $603,500.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO William J. Peters sold 6,226 shares of Amphastar Pharmaceuticals stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $19.67, for a total value of $122,465.42. The disclosure for this sale can be found here. Insiders sold 72,787 shares of company stock worth $1,359,684 over the last ninety days. 11.10% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Amphastar Pharmaceuticals (AMPH) Earns Daily Coverage Optimism Rating of 0.18” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/22/amphastar-pharmaceuticals-amph-earns-daily-coverage-optimism-rating-of-0-18.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.